Elan cures breach with Tysabri partner Biogen
Sep 15th, 2009 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Elan Corporation plc, the Irish listed drugs firm, on Monday announced that it has cured an "unintended breach" of its Tysabri Collaboration Agreement with US partner Biogen, by an agreement with Johnson & Johnson to cut the amount it will pay for its 18.4% stake in Elan by $115m to $885m.